Corporate news

SIPPET, an international randomized study, reports 87% higher incidence of inhibitors with recombinant factor VIII in patients with severe hemophilia A Results of the study have just been published in the May 26th issue of the New England Journal of Medicine
+ info

Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division The company has announced a new industrial expansion plan and continues with its initiatives to increase access to plasma
+ info



We are a solid company with an international dimension.

Corporate Commitment

We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.

When a Dream Comes True. An Illustrated History of 75 Years of Grifols

Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company.  + info


get to know us better